Connection

CLIONA ROONEY to Cell Proliferation

This is a "connection" page, showing publications CLIONA ROONEY has written about Cell Proliferation.
Connection Strength

1.453
  1. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010 Apr; 33(3):305-15.
    View in: PubMed
    Score: 0.208
  2. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells. J Transl Med. 2019 07 24; 17(1):240.
    View in: PubMed
    Score: 0.099
  3. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139.
    View in: PubMed
    Score: 0.089
  4. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017 11; 7(11):1238-1247.
    View in: PubMed
    Score: 0.087
  5. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3499-3509.
    View in: PubMed
    Score: 0.084
  6. Large-Scale Culture and Genetic Modification of Human Natural Killer Cells for Cellular Therapy. Methods Mol Biol. 2016; 1441:195-202.
    View in: PubMed
    Score: 0.078
  7. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36.
    View in: PubMed
    Score: 0.072
  8. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
    View in: PubMed
    Score: 0.067
  9. Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica. 2013 Apr; 98(4):533-7.
    View in: PubMed
    Score: 0.063
  10. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy. 2012 Jan; 14(1):7-11.
    View in: PubMed
    Score: 0.059
  11. Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Mol Ther. 2011 Dec; 19(12):2239-48.
    View in: PubMed
    Score: 0.057
  12. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther. 2010 Nov; 18(11):2006-17.
    View in: PubMed
    Score: 0.054
  13. IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol. 2010 Oct 01; 185(7):4223-32.
    View in: PubMed
    Score: 0.054
  14. In vivo fluorescent optical imaging of cytotoxic T lymphocyte migration using IRDye800CW near-infrared dye. Appl Opt. 2008 Nov 01; 47(31):5944-52.
    View in: PubMed
    Score: 0.047
  15. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74.
    View in: PubMed
    Score: 0.047
  16. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood. 2005 Jun 15; 105(12):4677-84.
    View in: PubMed
    Score: 0.037
  17. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258.
    View in: PubMed
    Score: 0.021
  18. Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Cytotherapy. 2014 Sep; 16(9):1257-69.
    View in: PubMed
    Score: 0.018
  19. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83.
    View in: PubMed
    Score: 0.017
  20. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in?vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1252-7.
    View in: PubMed
    Score: 0.017
  21. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014 Jun 12; 123(24):3750-9.
    View in: PubMed
    Score: 0.017
  22. Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes. J Immunol. 2011 Nov 15; 187(10):5221-32.
    View in: PubMed
    Score: 0.015
  23. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011 Sep; 13(8):976-86.
    View in: PubMed
    Score: 0.014
  24. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010 Nov-Dec; 33(9):983-90.
    View in: PubMed
    Score: 0.014
  25. Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes. J Immunother. 2009 Sep; 32(7):726-36.
    View in: PubMed
    Score: 0.013
  26. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009 Oct; 17(10):1779-87.
    View in: PubMed
    Score: 0.012
  27. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov; 14(11):1264-70.
    View in: PubMed
    Score: 0.012
  28. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008 Jun; 31(5):500-5.
    View in: PubMed
    Score: 0.011
  29. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007 Jun 15; 67(12):5957-64.
    View in: PubMed
    Score: 0.011
  30. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 01; 110(7):2620-30.
    View in: PubMed
    Score: 0.011
  31. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006 Dec 01; 108(12):3890-7.
    View in: PubMed
    Score: 0.010
  32. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother. 2006 May-Jun; 29(3):250-60.
    View in: PubMed
    Score: 0.010
  33. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May; 47(5):837-42.
    View in: PubMed
    Score: 0.010
  34. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother. 2006 Jan-Feb; 29(1):21-31.
    View in: PubMed
    Score: 0.010
  35. HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy. Eur J Immunol. 2005 Jul; 35(7):2250-8.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.